Moderna Inc
The rise of OpenAI and Microsoft’s $13 billion bet on the AI startup
OpenAI, the company behind the ChatGPT chatbot, was founded in 2015 by a number of researchers, academics and entrepreneurs, including Sam Altman, Greg Brockman and Elon Musk. Altman and Brockman are still at OpenAI, serving as CEO and president, respectively. Musk departed in 2018. At the time, OpenAI said Musk left to avoid a conflict […]
Read More
Disney and this AI stock are among the most oversold stocks this week and could be due for a bounce
The stock market clawed back from a global rout to finish higher Friday, but there still may be an opportunity for some names to rebound. Stocks had a rough start to the week. Disappointing payrolls data coupled with an unraveling of the yen “carry trade,” not to mention concerns that the Federal Reserve has waited […]
Read More
Stocks making the biggest moves midday: Shake Shack, C.H. Robinson, Mobileye Global and more
Check out the companies making headlines in midday trading: Shake Shack — The stock gained more than 15% after the burger chain’s revenue topped estimates. Shake Shack earned 27 cents per share, excluding items, on revenue of $316 million, above the LSEG estimate of $314 million. Shake Shack also narrowed its full-year revenue estimate to […]
Read More
Stocks making the biggest moves premarket: Hershey, Meta Platforms, Arm Holdings, Shake Shack and more
Check out the companies making headlines in premarket trading. Hershey — Shares were down 7% in the premarket after the chocolate maker posted second-quarter results that missed analyst expectations. The company earned $1.27 per share on revenue of $2.07 billion. Analysts polled by LSEG expected a profit of $1.43 per share on revenue of $2.31 […]
Read More
Moderna stock falls more than 10% as it slashes guidance on low EU sales, tough U.S. vaccine market
Moderna on Thursday reported second-quarter revenue that beat expectations but slashed its full-year sales guidance, citing lower expected sales in Europe, a “competitive environment” for respiratory vaccines in the U.S. and the potential for deferred international revenue into 2025. The biotech company now expects 2024 product revenue to come in between $3 billion to $3.5 […]
Read More
S&P 500 futures rise after Meta posts quarterly beat: Live updates
Traders work on the floor of the New York Stock Exchange. NYSE Stock futures rose in overnight trading Wednesday as investors weighed the latest corporate earnings reports, including strong results from Meta Platforms. S&P 500 futures gained 0.4%, while Nasdaq-100 futures jumped 0.7%. Futures tied to the Dow Jones Industrial Average added 30 points, or […]
Read More
Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline
Kena Betancur | Corbis News | Getty Images Pfizer had a “phenomenal” first quarter — and Wall Street took notice, CEO Albert Bourla told thousands of employees during a companywide town hall on May 2, according to a recording heard by CNBC. A day earlier, the pharmaceutical giant’s stock had closed 6% higher after its […]
Read More
Healthy Returns: What we know about the next round of Covid vaccines
New vaccine COMIRNATY® (COVID-19 Vaccine, mRNA) by Pfizer, available at CVS Pharmacy in Eagle Rock, CA. Irfan Khan | Los Angeles Times | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! It’s almost that time of the year again. A new […]
Read More
Moderna’s combination Covid, flu vaccine is more effective than existing shots in late-stage trial
Empty bottles of Moderna’s Covid-19 vaccine. Fred Tanneau | AFP | Getty Images Moderna on Monday said its combination vaccine that targets both Covid-19 and the flu was more effective than existing standalone shots for those viruses in a late-stage trial. The biotech company is the first to release positive phase three data on a […]
Read More
FDA approves GSK’s RSV vaccine for high-risk adults ages 50 to 59, expanding shot’s reach
A view shows GlaxoSmithKline headquarters in London, Britain, January 17, 2022. Hannah Mckay | Reuters The Food and Drug Administration on Friday expanded the approval of GSK‘s respiratory syncytial virus vaccine to adults ages 50 to 59 who are at increased risk of getting severely sick from the potentially lethal virus. The shot, called Arexvy, […]
Read More